Welcome / Velkommen
Our research focusses on basic molecular mechanisms and new treatment options for neurodegenerative diseases with special emphasis on Alzheimer’s disease. We investigate clearance mechanisms of toxic peptides via the blood-brain barrier, new imaging techniques, mitochondrial function, and neuroimmunological mechanisms. Our work also includes Parkinson’s, Huntington’s, ALS and other proteopathies of the brain. If you are interested to collaborate with us, please do not hesitate to get in contact.
Aug 3rd: Sideritis spp. extracts enhance memory and learning in Alzheimer’s β-amyloidosis mouse models and aged C57Bl/6 mice.
Journal of Alzheimer’s disease
Nowadays, dementia is the most prevalent epiphenomenon of the aging population. Preserving or regaining cognitive functions is one of the most desperate needs of elderly with mild cognitive impairment (MCI) or clinically overt dementia, most frequently caused by Alzheimer’s disease (AD). Although soluble β-amyloid (Aβ) species (monomers, oligomers) are recognized triggers for progressing memory decline and neuronal damage in AD brains, no therapeutic approach is able to stop it yet. Herbal medicines are used to treat different diseases in many regions of the world. On the Balkan Peninsula, at the eastern Mediterranean Sea, and adjacent regions Sideritis species are intensely used as traditional medicine in form of teas or ethanolic tinctures, also to prevent age-related cognitive problems in elderly. To evaluate this traditional knowledge in a controlled experiment, we tested extracts of two commonly used Sideritis species, Sideritis euboea and Sideritis scardica, with regard to their effects on cognitiong in APP-transgenic and aged, non-transgenic C57Bl/6 mice. Additionally, histomorphological and biochemical changes associated with Aβ deposition and treatment were assessed.
We found that daily oral treatment with Sideritis spp. extracts highly enhanced cognition in aged, non-transgenic as well as in APP-transgenic mice, an effect that was even more pronounced when extracts of both species were applied in combination. The treatment strongly reduced Aβ42 load in APP-transgenic mice, accompanied by increased phagocytic activity of microglia, and increased expression of the α-secretase ADAM10. Moreover, the treatment was able to fully rescue neuronal loss of APP-transgenic mice to normal levels as seen in non-transgenic controls. Having the traditional knowledge in mind, our results imply that treatment with Sideritis spp. extracts might be a potent, well tolerated option for treating symptoms of cognitive impairment in elderly and with regard to Alzheimer’s disease by affecting its most prominent hallmarks: Aβ pathology and cognitive decline.
Newest press releases
1. Skal finne ut om Alzheimers smitter
Kan Alzheimers overføres fra syke til friske mennesker? Norsk forsker tror ikke det, men skal komme til bunns i.
2. Our team has recently published results in the prestigious scientific journal ‘BRAIN’
showing that decreased removal of toxic peptides in the brain causes the onset and first clinical signs of Alzheimer’s disease, rather than overproduction as has previously been assumed. This information can now be used to target specific genes to enhance their function in the brain of elderly or people at risk.
Krohn M, Bracke A, Avchalumov Y, Schumacher T, Hofrichter J, Paarmann K, Fröhlich C, Lange C, Brüning T, von Bohlen und Halbach Oliver, Pahnke Jens (2015): Accumulation of murine β-amyloid mimics early Alzheimer’s disease. Brain, (PubMed …, Brain …)
Anwendung von Johanniskraut und Griechischem Bergtee
Hier ein Link zu Rückmeldungen von Patienten / Angehörigen zu Behandlungen bei dementieller Symptomatik. Publizierte wissenschaftliche Daten finden Sie unter ‘publications’.
Norske forskere i europeisk kamp mot hjernesykdommer
En stor gruppe europeiske land og Canada bestemte seg i 2011 for å innlede en intens forskningsbasert kamp mot Alzheimer og andre hjerneødeleggende sykdommer. I 2013 fikk tre norske forskergrupper penger til å bli med i kampen, og nå har ytterligere tre norske grupper fått bevilgning.
Information for patients and their relatives
How patients can help us:
Currently, we are investigating new genetic markers for the determination of new treatment options using ABC transport-activating drugs. We are seeking for patients and their relatives (as control group) with neurodegenerative disorders, e.g. Alzheimer’s, Parkinson’s, ALS, FTLD, Huntington’s and rare diseases. We are also looking for persons whos parents were affected by dementia. The procedure only includes a questionaire and a donation of blood. The blood can be taken by the local practitioner and then sent to us by mail. There is no need to come to our lab.
Many thanks for supporting dementia research.
Please contact us for questions:
Tel in Norway: +47 230 71466